[go: up one dir, main page]

CN109983007A - 酰胺类衍生物抑制剂及其制备方法和应用 - Google Patents

酰胺类衍生物抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN109983007A
CN109983007A CN201880004515.5A CN201880004515A CN109983007A CN 109983007 A CN109983007 A CN 109983007A CN 201880004515 A CN201880004515 A CN 201880004515A CN 109983007 A CN109983007 A CN 109983007A
Authority
CN
China
Prior art keywords
alkyl
naphthenic base
heterocycle
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004515.5A
Other languages
English (en)
Other versions
CN109983007B (zh
Inventor
高鹏
孙广俊
王少宝
张福军
刘磊
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN109983007A publication Critical patent/CN109983007A/zh
Application granted granted Critical
Publication of CN109983007B publication Critical patent/CN109983007B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

涉及酰胺类衍生物抑制剂、其制备方法和应用。特别地，涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为ASK1抑制剂在治疗神经退休性疾病、心血管疾病、炎症、自身免疫和代谢性疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201880004515.5A 2017-03-03 2018-03-02 酰胺类衍生物抑制剂及其制备方法和应用 Active CN109983007B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017101237997 2017-03-03
CN201710123799 2017-03-03
CN201710713967 2017-08-18
CN2017107139678 2017-08-18
CN2018100450232 2018-01-17
CN201810045023 2018-01-17
PCT/CN2018/077869 WO2018157856A1 (zh) 2017-03-03 2018-03-02 酰胺类衍生物抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109983007A true CN109983007A (zh) 2019-07-05
CN109983007B CN109983007B (zh) 2021-11-05

Family

ID=63369764

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211259633.5A Active CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用
CN201880015032.5A Active CN111094250B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用
CN201880004515.5A Active CN109983007B (zh) 2017-03-03 2018-03-02 酰胺类衍生物抑制剂及其制备方法和应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202211259633.5A Active CN115504986B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用
CN201880015032.5A Active CN111094250B (zh) 2017-03-03 2018-03-02 凋亡信号调节激酶抑制剂及其制备方法和应用

Country Status (7)

Country Link
US (1) US11136324B2 (zh)
EP (1) EP3590931A4 (zh)
JP (1) JP7211959B2 (zh)
KR (1) KR20190126322A (zh)
CN (3) CN115504986B (zh)
TW (1) TW201833108A (zh)
WO (2) WO2018157857A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109400625A (zh) * 2017-08-17 2019-03-01 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN110577536A (zh) * 2019-07-16 2019-12-17 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN111107848A (zh) * 2018-08-10 2020-05-05 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN111132984A (zh) * 2018-08-14 2020-05-08 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
CN110869017B (zh) 2017-05-12 2023-05-05 英安塔制药有限公司 细胞凋亡信号调节激酶1抑制剂及其使用方法
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018233553A1 (zh) * 2017-06-19 2018-12-27 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
TW201908306A (zh) * 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
CN109232538B (zh) * 2017-10-12 2020-07-24 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
JP7271540B2 (ja) 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Ａｓｋ１阻害剤としての尿素誘導体
CN109956928B (zh) * 2017-12-14 2021-07-09 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
WO2019136025A1 (en) 2018-01-02 2019-07-11 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110294746B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用
EP3773577B1 (en) 2018-04-12 2024-11-20 Terns, Inc. Tricyclic ask1 inhibitors
IL278368B2 (en) 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
HUE068695T2 (hu) 2018-05-08 2025-01-28 Nippon Shinyaku Co Ltd Azabenzimidazol vegyületek és gyógyszerek
AU2019271279A1 (en) 2018-05-17 2020-11-26 Forma Therapeutics, Inc. Fused bicyclic compounds useful as Ubiquitin-Specific Peptidase 30 inhibitors
JP7096460B2 (ja) * 2018-07-20 2022-07-06 福建▲広▼生中霖生物科技有限公司 Ａｓｋ１阻害剤としての結晶形、その製造方法及び利用
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN110922407B (zh) * 2018-09-19 2021-11-12 广东东阳光药业有限公司 苯甲酰氨基吡啶衍生物的晶型及其用途
BR112021003620A2 (pt) 2018-10-05 2021-05-18 Forma Therapeutics, Inc. pirrolinas fundidas que atuam como inibidoras da protease específica para a ubiquitina 30 (usp30)
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
KR102288434B1 (ko) * 2018-10-18 2021-08-12 에이치케이이노엔 주식회사 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도
CN111170995A (zh) * 2018-11-09 2020-05-19 山东轩竹医药科技有限公司 Ask1抑制剂及其应用
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
WO2021031071A1 (zh) * 2019-08-19 2021-02-25 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
EP4059933A4 (en) 2019-11-13 2023-11-15 Nippon Shinyaku Co., Ltd. AZABENZIMIDAZOLE COMPOUND AND DRUG
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactemic agents and their use as inhibitors of hpk1
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
CN113831323B (zh) * 2020-06-24 2025-08-29 武汉人福创新药物研发中心有限公司 芳杂环酰胺类化合物及其用途
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2023546055A (ja) * 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN104080771A (zh) * 2012-01-27 2014-10-01 吉利德科学公司 细胞凋亡信号调节激酶抑制剂
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
WO2016105453A1 (en) * 2014-12-23 2016-06-30 Gilead Sciences, Inc. Solid forms of an ask1 inhibitor
CN109071538A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
JP5320291B2 (ja) 2006-07-14 2013-10-23 ケモセントリックス， インコーポレイテッド トリアゾリルピリジルベンゼンスルホンアミド類
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
PL2588475T3 (pl) 2010-07-02 2015-10-30 Gilead Sciences Inc Inhibitory kinazy regulującej sygnał apoptozy
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
HK1226073A1 (zh) 2013-12-20 2017-09-22 吉利德科学公司 凋亡信號調節激酶的抑制劑
TWI749934B (zh) 2014-12-23 2021-12-11 美商基利科學股份有限公司 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法
CN110036005B (zh) * 2016-11-16 2022-09-27 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
CN107793400B (zh) * 2017-10-31 2020-01-31 武汉九州钰民医药科技有限公司 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN104080771A (zh) * 2012-01-27 2014-10-01 吉利德科学公司 细胞凋亡信号调节激酶抑制剂
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
WO2016105453A1 (en) * 2014-12-23 2016-06-30 Gilead Sciences, Inc. Solid forms of an ask1 inhibitor
CN109071538A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAS: "1518316-27-2、1508008-76-1、1506777-35-0", 《STN REGISTRY》 *
MARION LANIER等: "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure", 《ACS MEDICINAL CHEMISTRY LETTERS》 *
TONY S. GIBSON等: "Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109400625A (zh) * 2017-08-17 2019-03-01 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN109400625B (zh) * 2017-08-17 2021-11-12 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN111107848A (zh) * 2018-08-10 2020-05-05 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN111132984A (zh) * 2018-08-14 2020-05-08 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
CN110577536A (zh) * 2019-07-16 2019-12-17 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用

Also Published As

Publication number Publication date
KR20190126322A (ko) 2019-11-11
JP7211959B2 (ja) 2023-01-24
EP3590931A4 (en) 2020-11-18
CN115504986A (zh) 2022-12-23
EP3590931A1 (en) 2020-01-08
CN115504986B (zh) 2024-05-14
US11136324B2 (en) 2021-10-05
JP2020509041A (ja) 2020-03-26
CN111094250A (zh) 2020-05-01
CN109983007B (zh) 2021-11-05
WO2018157857A1 (zh) 2018-09-07
TW201833108A (zh) 2018-09-16
WO2018157856A1 (zh) 2018-09-07
CN111094250B (zh) 2022-11-04
US20210032249A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
CN109983007A (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN105163584B (zh) 用于治疗癌症的化合物
CN109328187A (zh) 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2013532727A5 (zh)
CA2687265A1 (en) P70 s6 kinase inhibitors
CN102775356B (zh) 4-氨基喹唑啉衍生物及其应用
HRP20050967A2 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
RU2016110755A (ru) Соединение, ингибирующее активности киназ ВТК и/или JAK3
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
CA2718383A1 (en) Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases
JP2007519694A5 (zh)
CN111601797A (zh) 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
CN110049969A (zh) 喹啉类化合物、其制备方法及其医药用途
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
CN110267954A (zh) 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
CN103127095A (zh) 二氢噻吩酮衍生物作为pfDHODH抑制剂的合成及应用
IL283368B2 (en) Imidazo[2,1-b]pyridazin-7-yl urea compound and medicament containing the compound
JP2015522607A5 (zh)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
CN109952298A (zh) 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
KR20180110151A (ko) 치환된 아미노 6원 질소 헤테로고리계 화합물 및 이의 제조와 용도
RU2006138864A (ru) Ингибиторы митотического кинезина

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003699

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant